Development of next-generation antibody (HF-RabMab)

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K06923
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Biofunction/Bioprocess
• Research Institution: Kyoto Institute of Technology
• Principal Investigator: Kumada Yoichi 京都工芸繊維大学, 分子化学系, 准教授 (70452373)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: scFv / RabMab / CDR-grafting / production

Outline of Final Research Achievements

In this study, we demonstrated screening, production and CDR-grafting of a novel rabbit monoclonal antibody (RabMab), and also investigated a possibility of RabMab to use as a biologics. Antigen-specific RabMab clones were efficiently isolated by phage display system, and then, they were successfully produced in recombinant E. coli, Insect and animal cells with different fragment styles. CDR-grafting of RabMab was also possible. Thus we could confirm that RabMab has a great potential and usefulness to use in clinical trials.

Free Research Field

生物化学工学

Academic Significance and Societal Importance of the Research Achievements

本研究では、抗原特異性ならびに親和性に定評のあるウサギモノクローナル抗体（RabMab）の単離技術、生産技術、特異性変換技術を確立することに成功した。その結果、あらゆる抗原に対するRabMabを自在に単離、生産することが可能となった。本研究成果は、医薬品開発や検査薬開発の迅速化・効率化に大きく貢献できると考えられる。